Literature DB >> 29293245

The benefits of immunotherapy combinations.

Charles Schmidt.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 29293245     DOI: 10.1038/d41586-017-08702-7

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  36 in total

Review 1.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 3.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

4.  DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure.

Authors:  Liesl Jacobs; Elien De Smidt; Nick Geukens; Paul Declerck; Kevin Hollevoet
Journal:  Mol Ther       Date:  2020-02-13       Impact factor: 11.454

5.  Deleting key autophagy elongation proteins induces acquirement of tumor-associated phenotypes via ISG15.

Authors:  EunBin Kong; Hag Dong Kim; Joon Kim
Journal:  Cell Death Differ       Date:  2020-03-03       Impact factor: 15.828

6.  Injectable Liposome-based Supramolecular Hydrogels for the Programmable Release of Multiple Protein Drugs.

Authors:  Santiago Correa; Abigail K Grosskopf; John H Klich; Hector Lopez Hernandez; Eric A Appel
Journal:  Matter       Date:  2022-03-21

7.  Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery.

Authors:  Antonio E Barberio; Sean G Smith; Santiago Correa; Cathy Nguyen; Bang Nhan; Mariane Melo; Talar Tokatlian; Heikyung Suh; Darrell J Irvine; Paula T Hammond
Journal:  ACS Nano       Date:  2020-09-05       Impact factor: 15.881

8.  A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.

Authors:  Daniel Gallacher; Peter Auguste; Pamela Royle; Hema Mistry; Xavier Armoiry
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

Review 9.  Beyond immune checkpoint blockade: emerging immunological strategies.

Authors:  Shawn P Kubli; Thorsten Berger; Daniel V Araujo; Lillian L Siu; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2021-03-08       Impact factor: 84.694

10.  Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management.

Authors:  Giuseppe Fanciulli; Sergio Di Molfetta; Andrea Dotto; Tullio Florio; Tiziana Feola; Annamaria Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.